The history of Eurofins Biomnis

• 1897

  History

  Marcel Mérieux, a student of Louis Pasteur (Institut Pasteur), establishes Laboratory Marcel Mérieux in Lyon, France, specialising in microbiology.

• 1937

  History

  Dr. Charles Mérieux takes over his father’s laboratory.

• 1947

  History

  Charles Mérieux creates the French Institute of Foot-and-mouth Disease amongst the Lyonnaise abattoirs and then the Mérieux Institute.

• 1982

  History

  A department of Medically Assisted Procreation (MAP), focusing on couple’s infertility is integrated into Laboratory Marcel Mérieux.

• 1990

  Technology

  First application of the Polymerase Chain Reaction (PCR) technique, discovered at the end of the 80s, for infectious diseases (Virus, bacteria, parasite screening).

• 1993

  Technology

  Development of PCR technique for application in molecular biology.

• 1996

  History

  Laboratory Marcel Mérieux acquires the department of specialised pathology from the Institut Pasteur of Lyon

• 1998

  Technology

  Certification for the screening of Trisomy 21

• 1999

  History

  Laboratory Marcel Mérieux acquires a well-known specialised pathology lab in Ireland, Claymon Laboratories

• 2000

  History

  Laboratory Marcel Mérieux acquires Laboratory LCL (Claude Levy), pioneer of radio-immunology in France

• 2004

  Technology

  Creation of the Genetic Fingerprinting Laboratory whose mission is to establish genetic profiles for the French Justice System.

• 2008

  History

  Merger of Laboratory Marcel Merieux and Laboratory Claude Levy to form Biomnis, French leader in specialised medical pathology.

• 2008

  Technology

  Creation of the onco-haematology department, dedicated to the pathologies of malignant haemopathies and solid tumours.

• 2008

  Technology

  Development of the first therapeutic markers, notably KRAS for colorectal cancer and HER2 for breast cancer.

• 2013

  Technology

  Biomnis offers new oncology markers: HE4 and Roma score for early diagnosis of ovarian cancer, Septin 9 and [-2] proPSA & Phi index respectively for non-invasive screening of colon and prostate cancers.

• 2013

  Technology

  Development of NGS technique (New Generation Sequencing) enabling the sequencing of hundreds of thousands of DNA fragments for the diagnosis of genetic diseases.

• 2014

  Technology

  Biomnis develops an innovative, specialised new test for women via its new screening marker for pre-eclampsia in the 1st trimester of pregnancy.

• 2014

  Technology

  Application of NGS method to the Non-Invasive Prenatal Testing of trisomies 13, 18 and 21

• 2014

  Technology

  Mass Spectrometry as chosen method for immunosuppressant drug testing and the therapeutic monitoring of transplanted patients. With over 400 specimens tested per day, Biomnis laboratories is placed n° 1 in Europe for the testing of these immunosuppressants by LC-MS-MS.

• 2015

  History

  Biomnis Laboratories joins Eurofins Group, global leader of bio-analytical testing.
  

• 2015

  Technology

  Performance of new companion diagnostic tests for personalised medicine in oncology, enabling chemotherapy dose adjustment (5-FU).